Could Arbutus Biopharma’s Patent Harm Moderna?

Arbutus Biopharma and Moderna's Patent Challenge
Arbutus Biopharma (ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering and developing a cure for patients suffering from chronic hepatitis B infection.

The stock has been in the Aggressive Table of the This content is for paid subscribers.

Please click here to subscribe or here to log in.